Arsanis, which is developing antibodies designed to prevent serious infectious diseases, filed on Friday with the SEC to raise up to $58 million in an initial public offering.
The Waltham, MA-based company was founded in 2010 and plans to list on the Nasdaq under the symbol ASNS. Arsanis filed confidentially on August 10, 2017. Citi, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
